DBV Technologies S.A. (NASDAQ: DBVT)

DBV Technologies S.A. specializes in the development of innovative treatments for food allergies, focusing on its proprietary Epicutaneous Immunotherapy (EPIT) technology. The company operates within the biopharmaceutical industry, specifically targeting the unmet medical needs of patients suffering from food allergies, particularly peanut allergies. Its core business revolves around the research, development, and potential commercialization of therapeutic products designed to induce immune tolerance in allergic individuals through non-invasive methods.

The company generates revenue through the development and potential commercialization of its lead product candidate, Viaskin Peanut, which is designed to treat peanut allergies. Viaskin Peanut is a key component of DBV's product pipeline, representing the company's primary focus in the allergy treatment market. The company's revenue model is currently centered on securing funding for clinical trials, partnerships, and potential future sales of its therapeutic products. DBV Technologies S.A. aims to cater to a broad customer base, including patients, healthcare providers, and regulatory bodies, with the ultimate goal of providing effective and safe treatments for food allergies.

• Viaskin Peanut: This product is designed to treat peanut allergies using EPIT technology, which delivers allergen-specific immunotherapy through the skin. The product is intended for use in pediatric and adolescent populations, aiming to induce immune tolerance and reduce the risk of severe allergic reactions. The Viaskin Peanut patch is a key component of DBV's product pipeline, representing the company's primary focus in the allergy treatment market.

DBV Technologies S.A. operates in a competitive landscape within the biopharmaceutical industry, particularly in the allergy treatment sector. The company faces competition from other pharmaceutical and biotechnology firms developing treatments for food allergies. Key competitors include Aimmune Therapeutics, Inc., which developed Palforzia, a peanut allergy treatment that has been approved by the FDA and the European Commission. Nestlé S.A. acquired Aimmune in October 2020 and divested the Palforzia business to Stallergenes Greer in September 2023. Additionally, Stallergenes Greer announced in December 2025 that it intends to discontinue the commercialization of Palforzia, creating a potential opportunity for DBV Technologies S.A. to capture market share. The company's competitive advantages include its proprietary EPIT technology, which offers a non-invasive and potentially safer alternative to existing treatments. DBV's focus on pediatric and adolescent populations also positions it uniquely within the market, addressing a critical need for effective allergy treatments in these age groups.

The company's customer base includes patients suffering from food allergies, healthcare providers, and regulatory bodies. While specific customer names are not provided, DBV Technologies S.A. aims to serve a broad range of stakeholders, including those involved in the development, approval, and distribution of its therapeutic products. The company's ultimate goal is to provide effective and safe treatments for food allergies, addressing the unmet medical needs of patients and improving their quality of life.